Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Armata Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DESCRIBES THE STRUCTURE OF PHAGE PA223, WHICH IS INCLUDED INARMATA'S MULTI-PHAGE ANTI-PSEUDOMONAS CLINICAL CANDIDATE, AP-PA02 LOS ANGELES , SEPT. 8, 2025 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED A PAPER IN THE JOURNAL OF MOLECULAR BIOLOGY (JMB).

ARMATA PHARMACEUTICALS ANNOUNCES STRUCTURAL BIOLOGY PUBLICATION IN THE JOURNAL OF MOLECULAR BIOLOGY

LOS ANGELES , SEPT. 4, 2025 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THATDEBORAH BIRX, M.D.

ARMATA PHARMACEUTICALS TO PARTICIPATE IN THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

ENTERED INTO SECURED CREDIT AGREEMENT WITH INNOVIVA FOR $15 MILLION MATURING IN 2029 ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE PHASE 1B/2A DISARM TRIAL FOR AP-SA02 LOS ANGELES , AUG. 12, 2025 /PRNEWSWIRE/ --ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE. SECOND QUARTER 2025 AND RECENT DEVELOPMENTS: ON AUGUST 11, 2025, ENTERED INTO A SECURED CREDIT AGREEMENT WITH INNOVIVA STRATEGIC OPPORTUNITIES LLC, A WHOLLY OWNED SUBSIDIARY OF INNOVIVA, INC., ARMATA'S LARGEST SHAREHOLDER, FOR A LOAN OF $15.0 MILLION THAT WILL MATURE ON JANUARY 11, 2029 PROCEEDS FROM THE NEW FINANCING TRANSACTION WILL BE USED TO CONTINUE TO ADVANCE DEVELOPMENT OFARMATA'S LEAD STAPHYLOCOCCUS AUREUS ("S.

ARMATA PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2025 RESULTS AND PROVIDES CORPORATE UPDATE

ALL PRIMARY ENDPOINTS FOR SAFETY, TOLERABILITY, AND CLINICAL RESPONSE IN THE INTENT-TO-TREAT POPULATION MET AP-SA02 ARM SIGNIFICANTLY IMPROVED CLINICAL OUTCOMES AND PREVENTED RELAPSE COMPARED TO BEST AVAILABLE ANTIBIOTIC THERAPY NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS WERE OBSERVED WITH REPETITIVE INTRAVENOUS DOSING LOS ANGELES , MAY 19, 2025 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM ITS PHASE 1B/2A DISARM TRIAL WHICH EVALUATED AP-SA02, A NOVEL INTRAVENOUS ("IV") ADMINISTERED MULTI-PHAGE THERAPEUTIC FOR THE TREATMENT OF S TAPHYLOCOCCUS AUREUS("S. AUREUS") BACTEREMIA ("SAB"), IN THE INTENT-TO-TREAT ("ITT") POPULATION.

ARMATA PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE DATA FROM THE PHASE 1B/2A DISARM STUDY OF INTRAVENOUSLY ADMINISTERED AP-SA02 IN COMPLICATED STAPHYLOCOCCUS AUREUS BACTEREMIA

LOS ANGELES , MAY 14, 2025 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A CORPORATE UPDATE. FIRST QUARTER 2025 AND RECENT DEVELOPMENTS: ANTICIPATING ANNOUNCEMENT OF TOPLINE RESULTS FROM PHASE 1B/2A DISARM STUDY OF INTRAVENOUS AP-SA02 AS A POTENTIAL TREATMENT FOR STAPHYLOCOCCUS AUREUS ("S.

ARMATA PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2025 RESULTS AND PROVIDES CORPORATE UPDATE

PHASE 1B/2A DISARM TRIAL EVALUATED AP-SA02 AS A POTENTIAL TREATMENT FOR COMPLICATED STAPHYLOCOCCUS AUREUS BACTEREMIA TOPLINE DATA ANTICIPATED IN Q2 2025 TO SUPPORT POTENTIAL FUTURE PIVOTAL BACTEREMIA EFFICACY TRIAL LOS ANGELES , MAY 1, 2025 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN:ARMP) ("ARMATA" OR THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT IT HAS RECEIVED AN ADDITIONAL $4.65 MILLION OF NON-DILUTIVE FUNDING PURSUANT TO A PREVIOUSLY ANNOUNCED DEPARTMENT OF DEFENSE (DOD) AWARD, RECEIVED THROUGH THE MEDICAL TECHNOLOGY ENTERPRISE CONSORTIUM (MTEC) AND MANAGED BY THE NAVAL MEDICAL RESEARCH COMMAND (NMRC)  NAVAL ADVANCED MEDICAL DEVELOPMENT (NAMD) WITH FUNDING FROM THE DEFENSE HEALTH AGENCY AND JOINT WARFIGHTER MEDICAL RESEARCH PROGRAM. THE AWARD, CURRENTLY TOTALING $26.2 MILLION, WAS AWARDED TO ARMATA TO SUPPORT CLINICAL DEVELOPMENT OF ITS OPTIMIZED PHAGE CANDIDATE, AP-SA02, AS A POTENTIAL TREATMENT FOR COMPLICATED STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB).

ARMATA PHARMACEUTICALS RECEIVES $4.65 MILLION OF ADDITIONAL NON-DILUTIVE AWARD FUNDING FROM THE U.S. DEPARTMENT OF DEFENSE TO SUPPORT ONGOING DISARM CLINICAL TRIAL OF AP-SA02

LOS ANGELES , MARCH 20, 2025 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY, PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS FOURTH QUARTER AND FULL-YEAR ENDED DECEMBER 31, 2024, AND PROVIDED A CORPORATE UPDATE. FOURTH QUARTER 2024 AND RECENT DEVELOPMENTS: ANNOUNCED ENCOURAGINGTOPLINE RESULTS FROM ITS PHASE 2 TAILWIND STUDY EVALUATING INHALED AP-PA02 AS A POTENTIAL TREATMENT FOR CHRONIC PULMONARY DISEASE; PSEUDOMONAS AERUGINOSA ("P.

ARMATA PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 RESULTS AND PROVIDES CORPORATE UPDATE

PROCEEDS TO BE USED TO CONTINUE TO ADVANCE DEVELOPMENT OFARMATA'S PHAGE PRODUCT CANDIDATES LOS ANGELES , MARCH 12, 2025 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURED CREDIT AGREEMENT WITH INNOVIVA STRATEGIC OPPORTUNITIES LLC, A WHOLLY-OWNED SUBSIDIARY OF INNOVIVA, INC. (NASDAQ: INVA) (COLLECTIVELY, "INNOVIVA"), ARMATA'S LARGEST SHAREHOLDER. THE GROSS PROCEEDS TO BE RECEIVED BY THE COMPANY AT CLOSING ARE $10 MILLION BEFORE DEDUCTING TRANSACTION-RELATED EXPENSES.

ARMATA PHARMACEUTICALS ANNOUNCES $10 MILLION SECURED CREDIT AGREEMENT WITH INNOVIVA

LOS ANGELES , MARCH 11, 2025 /PRNEWSWIRE/ --ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCEDTHAT DR.DEBORAH BIRX, CHIEF EXECUTIVE OFFICER, WILL DELIVER A PRESENTATION AT 9:00AM ET ON THURSDAY, MARCH 13, 2025AT THE 7TH ANNUAL BACTERIOPHAGE THERAPY SUMMIT, BEING HELD INBOSTON, MA. FOR MORE INFORMATION: HTTPS://BACTERIOPHAGE-SUMMIT.COM/ ABOUT ARMATA PHARMACEUTICALS, INC. ARMATA IS A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT AND DIFFICULT-TO-TREAT BACTERIAL INFECTIONS USING ITS PROPRIETARY BACTERIOPHAGE-BASED TECHNOLOGY.

ARMATA PHARMACEUTICALS ANNOUNCES THAT CEO DR. DEBORAH BIRX WILL DELIVER A PRESENTATION AT THE 7TH ANNUAL BACTERIOPHAGE THERAPY SUMMIT

RESULTS DEMONSTRATE THAT INHALED AP-PA02 PROVIDES A DURABLE REDUCTION OF PSEUDOMONAS AERUGINOSA IN THE LUNG, WITH A FAVORABLE SAFETY AND TOLERABILITY PROFILE LOS ANGELES , DEC. 19, 2024 /PRNEWSWIRE/ -- ARMATA PHARMACEUTICALS, INC. (NYSE AMERICAN: ARMP) ("ARMATA" OR THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF HIGH-PURITY PATHOGEN-SPECIFIC BACTERIOPHAGE THERAPEUTICS FOR CHRONIC PULMONARY DISEASES AND ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS, TODAY ANNOUNCED ENCOURAGING TOPLINE RESULTS FROM ITS PHASE 2 ("TAILWIND") TRIAL EVALUATING AP-PA02, A NOVEL, INHALED MULTI-PHAGE THERAPEUTIC FOR THE TREATMENT OF CHRONIC PULMONARY PSEUDOMONAS AERUGINOSA ("P.A." OR "P. AERUGINOSA") INFECTIONS IN NON-CYSTIC FIBROSIS BRONCHIECTASIS ("NCFB") PATIENTS.

ARMATA PHARMACEUTICALS ANNOUNCES ENCOURAGING RESULTS FROM THE PHASE 2 TAILWIND STUDY OF INHALED AP-PA02 IN NON-CYSTIC FIBROSIS BRONCHIECTASIS SUBJECTS WITH CHRONIC PULMONARY PSEUDOMONAS AERUGINOSA INFECTION

Armata Pharmaceuticals, Inc.

ARMP

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Armata Pharmaceuticals, Inc.

ARMP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ARMP